Selenium-doped calcium carbonate nanoparticles loaded with cisplatin enhance efficiency and reduce side effects

[Display omitted] Osteosarcoma is the bone tumor that most commonly affects children and teenagers with low survival rate because of metastatic relapse or recurrence. Cisplatin is a first-line chemotherapy for osteosarcoma. However, severe side effects limit its use in clinic. Selenium (Se) is an an...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2019-10, Vol.570, p.118638-118638, Article 118638
Main Authors: Zhao, Pengxuan, Li, Minsi, Chen, Yan, He, Chuanchuan, Zhang, Xiaojuan, Fan, Ting, Yang, Tan, Lu, Yao, Lee, Robert J., Ma, Xiang, Luo, Jun, Xiang, Guangya
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Bone Neoplasms - drug therapy
Calcium Carbonate - chemistry
Cell Line, Tumor
Cisplatin - chemistry
Cisplatin - pharmacology
Drug delivery
Emulsions - chemistry
Humans
Lipids - chemistry
Mice
Mice, Nude
Nanoparticles
Nanoparticles - chemistry
Osteosarcoma
Osteosarcoma - drug therapy
Selenium
Selenium - chemistry
Synergistic effect
Xenograft Model Antitumor Assays - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Osteosarcoma is the bone tumor that most commonly affects children and teenagers with low survival rate because of metastatic relapse or recurrence. Cisplatin is a first-line chemotherapy for osteosarcoma. However, severe side effects limit its use in clinic. Selenium (Se) is an anticarcinogen that can protect normal tissues from side effects of chemotherapy. In this study, nanoparticles were used to co-deliver cisplatin and Se in a synergistic combination. Se-doped and lipid-coated calcium carbonate nanoparticles loaded with cisplatin (Pt/Se@CaCO3 NPs) were prepared by a reverse microemulsion method. The NPs delivered cisplatin and Se to tumour cells at an optimal synergistic ratio of 1:1 (mol/mol) both in vitro and in an osteosarcoma xenograft model. These results demonstrate that Pt/Se@CaCO3 NPs have great prospects for the osteosarcoma therapy.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2019.118638